US3928609A - Non-alcoholic theophylline product - Google Patents
Non-alcoholic theophylline product Download PDFInfo
- Publication number
- US3928609A US3928609A US348076A US34807673A US3928609A US 3928609 A US3928609 A US 3928609A US 348076 A US348076 A US 348076A US 34807673 A US34807673 A US 34807673A US 3928609 A US3928609 A US 3928609A
- Authority
- US
- United States
- Prior art keywords
- theophylline
- vehicle
- alcoholic
- pharmaceutical composition
- propylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 title claims abstract description 63
- 229960000278 theophylline Drugs 0.000 title claims abstract description 32
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 235000011187 glycerol Nutrition 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 206010007522 Cardiac asthma Diseases 0.000 claims description 4
- 208000004327 Paroxysmal Dyspnea Diseases 0.000 claims description 4
- 239000002934 diuretic Substances 0.000 claims description 4
- 230000001882 diuretic effect Effects 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 19
- 235000019441 ethanol Nutrition 0.000 abstract description 13
- 238000000034 method Methods 0.000 abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 8
- 239000007788 liquid Substances 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 4
- 239000004615 ingredient Substances 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000036765 blood level Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010053155 Epigastric discomfort Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- KXRNMXPUTQVFOA-UHFFFAOYSA-L disodium;1,3-dimethyl-2-oxopurin-6-olate;acetate Chemical compound [Na+].[Na+].CC([O-])=O.CN1C(=O)N(C)C([O-])=C2N=CN=C21 KXRNMXPUTQVFOA-UHFFFAOYSA-L 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- UBVSIAHUTXHQTD-UHFFFAOYSA-N 2-n-(4-bromophenyl)-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(NC=2C=CC(Br)=CC=2)=N1 UBVSIAHUTXHQTD-UHFFFAOYSA-N 0.000 description 1
- NWPRCRWQMGIBOT-UHFFFAOYSA-N 7-(2-hydroxyethyl)-1,3-dimethylpurine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CCO)C=N2 NWPRCRWQMGIBOT-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000003555 analeptic effect Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229960003821 choline theophyllinate Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000012732 erythrosine Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- -1 glucamine Chemical compound 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- RLANKEDHRWMNRO-UHFFFAOYSA-M oxtriphylline Chemical compound C[N+](C)(C)CCO.O=C1N(C)C(=O)N(C)C2=C1[N-]C=N2 RLANKEDHRWMNRO-UHFFFAOYSA-M 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000009613 pulmonary function test Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Definitions
- ABSTRACT An improved liquid vehicle for a pharmaceutical composition of a mixture of propylene glycol and glycerine, a novel pharmaceutical composition of theophylline and this vehicle, comprising a composition which serves to solubilize the theophylline without ethyl alcohol, and the process for making the vehicle and the pharmaceutical composition are disclosed.
- compositions which include the type of compounds as the above agent have been used for the treatment in human patients of bronchiospasm, cardiac asthma, and as a diuretic, and in the veterinary field as an asthma remedy and heart mediamlant for animals.
- compositions are administered to humans orally, rectally or parenterally.
- rectal administration may produce local irritation and parenteral administration is often painful and sometimes dangerous, theophylline is commonly taken orally.
- an aqueous mixture of propylene glycol and glycerin have been found to be an effective liquid vehicle for a therapeutically active agent.
- the active ingredient for treatment of bronchial and cardiac asthma in the novel compositions of the invention is theophylline, its salts, complexes or derivatives thereof.
- These compounds include theophylline-ethylenediamine (aminophylline), theocin soluble (theophyllinesodium acetate), oxytocphylline (choline theophyllinate), theophylline-choline and 7-hydroxyethyltheophylline.
- the process according to the invention includes the mixing of a solution of the active agent suspended in glycerin with propylene glycol.
- various sweetening, flavoring, and coloring agents are preferably employed in preparing oral dosage forms of the present type.
- the pharmaceutical composition thus resulting is an oral dosage form of pure theophylline without alcohol which is stable at room temperature.
- the preferred form of theophylline is anhydrous in this composition, although other forms could be used by adjustment to correspond to differing molecular weights.
- the key ingredients in the solubilizing vehicle are propylene glycol (about 20%) and glycerine (about 3 10%). These maintain physical stability in variations of temperature.
- the therapeutically effective dosage level of theophylline was about 2-3 mg./kg. of body weight.
- the individual dosage of the oral theophylline for an adult is about 45cc, or 3 tablespoons, taken three times a day, with an additional 2 tablespoons at night. This may be increased for severe asthmatic attacks up to 5 tablespoons, but is limited for children to about a teaspoonful per pounds of body weight.
- Specific dosage generally varies with body weight, metabolism, and other individual characteristics.
- EXAMPLE The following example shows the ingredients used, methods of preparation, and therapeutic results obtained from the preferred embodiment of the invention.
- the theophylline is separately suspended with gentle agitation in heated glycerine at a temperature of 65-70C (Solution 2).
- Solution 2 is then dissolved in propylene glycol, previously heated to 65-70C, with gentle mixing while maintaining the temperature at 6570C until the resulting mixture becomes completely clear, after which time the mixing is continued for about 10 minutes.
- Solution 2 is then mixed with Solution 1.
- a heated sorbitol solution of about C is added with stirring.
- the mixture is cooled to 38C before adding flavor and bringing to final volume with purified water.
- the resulting syrup is cooled for a day and then filtered through a filter press at 30-40 psi.
- the mixture should have a pH of about 4.5 to maintain stability.
- results obtained The efficacy and acceptability of the preferred embodiment of the present invention has been shown in recent studies. For example, children ranging in ages between 8-12 suffering from asthma wheezing on a day-to-day basis were treated. Pulmonary function tests show improvement in overall condition. Blood serum concentration was also measured. Good blood levels were obtained, i.e., about 5 micrograms/ml. or greater in 15 to 30 minutes, and, in a few cases, in 5 minutes. The blood levels remained for up to 6 hours some as long as 8 hours. A blood concentration of 5 micrograms/ml. of theophylline is generally accepted by the art as a therapeutic concentration.
- a non-alcoholic composition for the treatment of bronchiospasm, cardiac asthma and as a diuretic consisting essentially of an effective amount of anhydrous theophyllin and a pharmaceutically acceptable vehicle consisting essentially of 20% propylene glycol and 10% glycerine and water.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An improved liquid vehicle for a pharmaceutical composition of a mixture of propylene glycol and glycerine, a novel pharmaceutical composition of theophylline and this vehicle, comprising a composition which serves to solubilize the theophylline without ethyl alcohol, and the process for making the vehicle and the pharmaceutical composition are disclosed.
Description
United States Patent 1191 Behrakis NON-ALCOHOLIC THEOPHYLLINE PRODUCT [75] Inventor: George D. Behrakis, Lowell, Mass.
[73] Assignee: Dooner Laboratories, Inc.,
Haverhill, Mass.
[22] Filed: Apr. 5, 1973 [21] Appl. No.: 348,076
3,309,271 3/1967 Georges 424/253 Dec. 23, 1975 9/1969 Mercer et a]. 424/253 4/1973 Klingler 424/253 OTHER PUBLICATIONS Husas Pharmaceutical Dispensing, 6th edition, 1966, pp. 273-277.
Primary Examiner-Norman A. Drezin Attorney, Agent, or Firm-James I-I. Wallace, Jr.
[57] ABSTRACT An improved liquid vehicle for a pharmaceutical composition of a mixture of propylene glycol and glycerine, a novel pharmaceutical composition of theophylline and this vehicle, comprising a composition which serves to solubilize the theophylline without ethyl alcohol, and the process for making the vehicle and the pharmaceutical composition are disclosed.
1 Claim, No Drawings NON-ALCOHOLIC THEOPHYLLINE PRODUCT BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates generally to a novel vehicle for pharmaceuticals, which improves the absorption of the active agent in the alimentary tract. More particularly, the invention concerns improved liquid pharmaceutical compositions of theophylline which solubilize the theophylline without ethyl alcohol and provide a stable solution.
2. Description of the Prior Art It has been long established that theophylline (1,3- dimethylxanthine), its salts and other derivatives, ex hibit bronchodilator, diuretic, analeptic, cardiac stimulant and coronary dilator properties. Therefore, compositions which include the type of compounds as the above agent have been used for the treatment in human patients of bronchiospasm, cardiac asthma, and as a diuretic, and in the veterinary field as an asthma remedy and heart stiumlant for animals.
Such compositions are administered to humans orally, rectally or parenterally. However, because rectal administration may produce local irritation and parenteral administration is often painful and sometimes dangerous, theophylline is commonly taken orally.
. This method of introduction into the human system, as is common with many other powerful drugs, also has several disadvantages in view of the active substances irregular absorption pattern, poor solubility and the tendency of the active ingredient or its carriers to irritate the gastrointestinal tract and cause vomiting. Thus, it is frequently difficult to' orally administer a sufficiently large dose of the agent to provide the desired therapeutic effect. Therefore, there is a need for an oral dosage from which will produce prompt effective concentrations of theophylline in the blood, maintain such concentrations, and produce minimal gastric irritation.
Various attempts have been made to overcome this difficulty by forming salts and complexes of theophylline with other compounds such as aluminum hydroxide, glucamine, sodium acetate. But this has not proved to be a satisfactory solution. The solubility is apparently improved only for alkaline conditions. Moreover, the active compound may even precipitate in the acidic environment of the stomach. Since these forms vary from about 49% to 80% of pure theophylline, higher dosages are needed to obtain adequate theophylline blood levels. Once dosage is increased, the common complaints associated with theophylline and its associated carriers are encountered, e.g., gastric irritation, nausea, vomiting, and overall discomfort.
Another approach taken is the use of ethanolic solutions to solubilize theophylline. This offered some improvement with better gastric tolerance and more prompt and adequate absorption of theophylline. The consensus generally had been that it was necessary to use alcohol to solubilize theophylline and that without alcohol, theophylline would be unstable and too poor an absorbent to be therapeutically effective. These solutions generally contain a high concentration of alcohol (from (30 proof) to (40 proof) ethyl alcohol. Accordingly, they cause problems in administration for children and for those unwilling or unable to ingest significant amounts of alcohol. Particularly with respect to children, who might need such medications for long periods of time, solutions containing alcohol are difficult to administer and represent a risk to the childs liver and general health. The term alcohol is not used in the generic sense but is intended to refer only to monohydroxy lower alkyl compounds such as ethanol, which is what the public considers as alcohol.
Descriptions of prior embodiments and methods can be found in the following patents: US. Pat. Nos. 2,975,099; 3,109,773; 3,109,775; 3,309,271; 3,467,754; 3,600,390; 3,632,742; Australia Pat. No. 261,738.
SUMMARY OF THE INVENTION Accordingly, it is an object of the present invention to provide a non-alcoholic theophylline dosage form having a sufficiently high concentration of theophylline without causing gastric distress.
Another object of the invention is to provide an oral dosage form of theophylline which will offer bioavailability and increased toleration and acceptance by chilcess of making the vehicle, which improves the stability and absorption of active therapeutic agents generally. Still another object of the invention is to provide an improved liquid vehicle for theophylline and the process for making the vehicle.
These and other objects will be apparent from the following disclosure.
DESCRIPTION OF THE PREFERRED EMBODIMENT In accordance with the present invention, an aqueous mixture of propylene glycol and glycerin have been found to be an effective liquid vehicle for a therapeutically active agent.
The active ingredient for treatment of bronchial and cardiac asthma in the novel compositions of the invention is theophylline, its salts, complexes or derivatives thereof.
These compounds include theophylline-ethylenediamine (aminophylline), theocin soluble (theophyllinesodium acetate), oxytocphylline (choline theophyllinate), theophylline-choline and 7-hydroxyethyltheophylline.
The process according to the invention includes the mixing of a solution of the active agent suspended in glycerin with propylene glycol. Of course, various sweetening, flavoring, and coloring agents are preferably employed in preparing oral dosage forms of the present type.
The pharmaceutical composition thus resulting is an oral dosage form of pure theophylline without alcohol which is stable at room temperature. The preferred form of theophylline is anhydrous in this composition, although other forms could be used by adjustment to correspond to differing molecular weights.
The key ingredients in the solubilizing vehicle are propylene glycol (about 20%) and glycerine (about 3 10%). These maintain physical stability in variations of temperature.
It had previously been believed that the therapeutically effective dosage level of theophylline was about 2-3 mg./kg. of body weight. However, recent scientific opinion holds that about 4-5 mg./kg. of body weight is desirable. The individual dosage of the oral theophylline for an adult is about 45cc, or 3 tablespoons, taken three times a day, with an additional 2 tablespoons at night. This may be increased for severe asthmatic attacks up to 5 tablespoons, but is limited for children to about a teaspoonful per pounds of body weight.
Specific dosage generally varies with body weight, metabolism, and other individual characteristics.
In order to illustrate the present invention the following example is provided.
EXAMPLE The following example shows the ingredients used, methods of preparation, and therapeutic results obtained from the preferred embodiment of the invention.
Ingredients A quantity of the preferred embodiment was prepared from the following ingredients:
Unit Amount/ (PFC 8432) (Polak Frutal Works) Purified H O QS Method of Preparation The above ingredients were prepared as follows:
1. The appropriate amounts of sodium benzoate, methyl paraben, sodium saccharin and citric acid are dissolved in heated purified water at a temperature from about 60-70C (Solution 1).
4 2. The theophylline is separately suspended with gentle agitation in heated glycerine at a temperature of 65-70C (Solution 2).
3. Solution 2 is then dissolved in propylene glycol, previously heated to 65-70C, with gentle mixing while maintaining the temperature at 6570C until the resulting mixture becomes completely clear, after which time the mixing is continued for about 10 minutes.
4. Solution 2 is then mixed with Solution 1.
5. A heated sorbitol solution of about C is added with stirring.
6. The FDC yellow No. 6 and FDC red No. 3 are dissolved in purified water and added to the above mixture.
7. The mixture is cooled to 38C before adding flavor and bringing to final volume with purified water.
8. The resulting syrup is cooled for a day and then filtered through a filter press at 30-40 psi. The mixture should have a pH of about 4.5 to maintain stability.
Results obtained The efficacy and acceptability of the preferred embodiment of the present invention has been shown in recent studies. For example, children ranging in ages between 8-12 suffering from asthma wheezing on a day-to-day basis were treated. Pulmonary function tests show improvement in overall condition. Blood serum concentration was also measured. Good blood levels were obtained, i.e., about 5 micrograms/ml. or greater in 15 to 30 minutes, and, in a few cases, in 5 minutes. The blood levels remained for up to 6 hours some as long as 8 hours. A blood concentration of 5 micrograms/ml. of theophylline is generally accepted by the art as a therapeutic concentration.
While one particular embodiment of this invention is shown above, it will be understood, of course, that the invention is not to be limited thereto, since many modifications may be made and it is contemplated, therefore, by the appended claims to cover such modifications as fall within the true spirit and scope of this invention.
What is claimed as new and intended to be covered by Letters Patent is:
l. A non-alcoholic composition for the treatment of bronchiospasm, cardiac asthma and as a diuretic consisting essentially of an effective amount of anhydrous theophyllin and a pharmaceutically acceptable vehicle consisting essentially of 20% propylene glycol and 10% glycerine and water.
Claims (1)
1. A NON-ALCOHOLIC COMPOSITION FOR THE TREATMENT OF BRONCHIOSPASM, CARDIAC ASTHMA AND AS A DIURETIC CONSISTING ESSENTIALLY OF AN EFFECTIVE AMOUNT OF ANHYDROUS THEOPHYLLIN AND A PHARMACEUTICALLY ACCEPTABLE VEHICLE CONSISTING ESSENTIALLY OF 20% PROPYLENE GLYCOL AND 10% GLYCERINE AND WATER.
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US348076A US3928609A (en) | 1973-04-05 | 1973-04-05 | Non-alcoholic theophylline product |
| CA195,262A CA1029657A (en) | 1973-04-05 | 1974-03-18 | Theophylline liquid preparation |
| AU66941/74A AU474309B2 (en) | 1973-04-05 | 1974-03-21 | Nonalcoholic theophylline product |
| DE2416216A DE2416216C2 (en) | 1973-04-05 | 1974-04-03 | Orally administrable pharmaceutical mixture |
| ZA00742156A ZA742156B (en) | 1973-04-05 | 1974-04-04 | Improvements in or relating to vehicles for pharmaceutical compositions |
| FR7412199A FR2224160A1 (en) | 1973-04-05 | 1974-04-05 | |
| GB1522874A GB1453234A (en) | 1973-04-05 | 1974-04-05 | Liquid vehicle for pharmaceutical compositions |
| JP3807474A JPS5427881B2 (en) | 1973-04-05 | 1974-04-05 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US348076A US3928609A (en) | 1973-04-05 | 1973-04-05 | Non-alcoholic theophylline product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3928609A true US3928609A (en) | 1975-12-23 |
Family
ID=23366547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US348076A Expired - Lifetime US3928609A (en) | 1973-04-05 | 1973-04-05 | Non-alcoholic theophylline product |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US3928609A (en) |
| JP (1) | JPS5427881B2 (en) |
| AU (1) | AU474309B2 (en) |
| CA (1) | CA1029657A (en) |
| DE (1) | DE2416216C2 (en) |
| FR (1) | FR2224160A1 (en) |
| GB (1) | GB1453234A (en) |
| ZA (1) | ZA742156B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4117132A (en) * | 1976-04-02 | 1978-09-26 | Dr. Adolf Seebach Ag | Process for the production of stabilized pure theophylline in neutral, aqueous solution |
| US4364922A (en) * | 1980-10-14 | 1982-12-21 | University Of Virginia Alumni Patents Foundation | Adenosine antagonists in the treatment and diagnosis of A-V node conduction disturbances |
| US4708957A (en) * | 1984-08-29 | 1987-11-24 | Schering Aktiengesellschaft | Injection solution |
| US5077296A (en) * | 1987-12-03 | 1991-12-31 | Hyal Pharmaceutical Corporation | Method for treating equine navicular disease with pentoxifylline, and composition containing pentoxifylline for administrating to horses |
| US5409619A (en) * | 1993-08-23 | 1995-04-25 | Reckitt & Colman Inc. | Ironing aid composition |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2531337A1 (en) * | 1982-08-04 | 1984-02-10 | Hoechst Lab | NEW ORALLY ADMINISTRATIVE GALENIC FORMS, SOLUBLE DIMETHYLXANTHINE DERIVATIVES |
| ZA853488B (en) * | 1984-05-10 | 1986-12-30 | American Home Prod | Transdermal dosage form |
| GB2551971B (en) * | 2016-06-29 | 2020-09-16 | Syri Ltd | Taste masked liquid pharmaceutical composition of mebeverine or pharmaceutically acceptable salts thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3109773A (en) * | 1961-10-25 | 1963-11-05 | Mead Johnson & Co | Bronchodilator expectorant composition containing theophylline and a guaiacol |
| US3134720A (en) * | 1962-06-27 | 1964-05-26 | Bristol Myers Co | Medicated gels |
| US3309271A (en) * | 1963-08-30 | 1967-03-14 | Manuf Prod Pharma | Methods and composition for inducing choleresis |
| US3467754A (en) * | 1966-08-10 | 1969-09-16 | Mead Johnson & Co | Bronchodilator expectorant elixir |
| US3728346A (en) * | 1971-07-16 | 1973-04-17 | Degussa | Hydroxyphenylhydroxyalkylaminoalkyltheophyllines |
-
1973
- 1973-04-05 US US348076A patent/US3928609A/en not_active Expired - Lifetime
-
1974
- 1974-03-18 CA CA195,262A patent/CA1029657A/en not_active Expired
- 1974-03-21 AU AU66941/74A patent/AU474309B2/en not_active Expired
- 1974-04-03 DE DE2416216A patent/DE2416216C2/en not_active Expired
- 1974-04-04 ZA ZA00742156A patent/ZA742156B/en unknown
- 1974-04-05 GB GB1522874A patent/GB1453234A/en not_active Expired
- 1974-04-05 JP JP3807474A patent/JPS5427881B2/ja not_active Expired
- 1974-04-05 FR FR7412199A patent/FR2224160A1/fr not_active Withdrawn
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3109773A (en) * | 1961-10-25 | 1963-11-05 | Mead Johnson & Co | Bronchodilator expectorant composition containing theophylline and a guaiacol |
| US3134720A (en) * | 1962-06-27 | 1964-05-26 | Bristol Myers Co | Medicated gels |
| US3309271A (en) * | 1963-08-30 | 1967-03-14 | Manuf Prod Pharma | Methods and composition for inducing choleresis |
| US3467754A (en) * | 1966-08-10 | 1969-09-16 | Mead Johnson & Co | Bronchodilator expectorant elixir |
| US3728346A (en) * | 1971-07-16 | 1973-04-17 | Degussa | Hydroxyphenylhydroxyalkylaminoalkyltheophyllines |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4117132A (en) * | 1976-04-02 | 1978-09-26 | Dr. Adolf Seebach Ag | Process for the production of stabilized pure theophylline in neutral, aqueous solution |
| US4364922A (en) * | 1980-10-14 | 1982-12-21 | University Of Virginia Alumni Patents Foundation | Adenosine antagonists in the treatment and diagnosis of A-V node conduction disturbances |
| US4708957A (en) * | 1984-08-29 | 1987-11-24 | Schering Aktiengesellschaft | Injection solution |
| AU588242B2 (en) * | 1984-08-29 | 1989-09-14 | Asche Aktiengesellschaft | Injection solution |
| US5077296A (en) * | 1987-12-03 | 1991-12-31 | Hyal Pharmaceutical Corporation | Method for treating equine navicular disease with pentoxifylline, and composition containing pentoxifylline for administrating to horses |
| US5409619A (en) * | 1993-08-23 | 1995-04-25 | Reckitt & Colman Inc. | Ironing aid composition |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2224160A1 (en) | 1974-10-31 |
| DE2416216C2 (en) | 1984-10-31 |
| JPS505522A (en) | 1975-01-21 |
| DE2416216A1 (en) | 1974-10-24 |
| AU474309B2 (en) | 1976-07-15 |
| ZA742156B (en) | 1975-04-30 |
| JPS5427881B2 (en) | 1979-09-12 |
| CA1029657A (en) | 1978-04-18 |
| GB1453234A (en) | 1976-10-20 |
| AU6694174A (en) | 1975-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1040532A (en) | Process for producing solid bismuth-containing pharmaceutical compositions | |
| US5374659A (en) | Aqueous pharmaceutical suspension for substantially water insoluble pharmaceutical actives | |
| JP3778518B2 (en) | Aqueous liquid composition with good taste for bitter drugs | |
| US5024997A (en) | Palatable ibuprofen solutions | |
| US3337402A (en) | Stable and palatable pharmaceutical composition | |
| KR101490721B1 (en) | Liquid Formulation for Deferiprone With Palatable Taste | |
| EP0524579B1 (en) | Improved oral dosing formulations of dideoxy purine nucleosides | |
| JPH0948728A (en) | Antipyretic and analgesic agent | |
| US3928609A (en) | Non-alcoholic theophylline product | |
| US3069321A (en) | Choline salicylate composition and methods of use | |
| EP0399051B1 (en) | Polyvalent antiinflammatory agent | |
| US4880835A (en) | Oral liquid pharmaceutical compositions of sulindac | |
| US4914121A (en) | 3-Phenyl-1-phenylpyrazole-4 acetic acid compounds which are useful in treating immune diseases | |
| US3144387A (en) | Anti-inflammatory compositions | |
| JPH09502709A (en) | Oral, water-soluble pharmaceutical composition containing estrone derivative and calcium salt | |
| US3109773A (en) | Bronchodilator expectorant composition containing theophylline and a guaiacol | |
| US20040116528A1 (en) | Ketoprofen compositons and methods of making them | |
| US4913901A (en) | Pharmaceutical composition for oral administration and process for the use thereof | |
| GB2577363A (en) | Liquid pharmaceutical composition for oral administration comprising paracetamol and codeine phosphate | |
| USRE29359E (en) | Bronchodilator expectorant composition containing theophylline and a guaiacol | |
| JP2001501225A (en) | Aqueous formulation containing bambbuterol and use thereof | |
| US4062974A (en) | Method for treating drepanocytosis | |
| US3914433A (en) | Method of relieving the discomfort of pharyngitis | |
| US4177281A (en) | Therapeutic treatment for measles viral infection | |
| JPS63313725A (en) | Syrup agent |